EGFR and glioma: These in silico studies led to the discovery of 18 candidate inhibitors for EGFR, 6 for PI3Kp110β, and 3 dual inhibitors of both targets, which efficacy against glioma cells was validated in parental and EGFR overexpressing cell lines [39].